# Safety and Efficacy of Modern Stents in Patients with Metabolic Syndrome
## 3 Results
### Medication at Discharge  
Over 50% of study participants received all five guideline-recommended medications (i.e., _acetylsalicylic acid_, purinergic receptor P2Y12 inhibitors, \(\beta\)-blocker, angiotensin  
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Variable, Mean \(\pm\) SD** & **2 nd Generation DES** & **Other Stents** & \\  & **(_n = 151_)** & **(_n = 53_)** & **\(p\)-Value** \\ \hline WBC (10\({}^{9}\)/L) & 10.93 \(\pm\) 3.56 & 11.13 \(\pm\) 4.02 & 0.73 \\ Creating (mg/dL) & 1.03 \(\pm\) 0.41 & 1.07 \(\pm\) 0.67 & 0.61 \\ GFR (mL/min/1.73 m\({}^{2}\)) & 75.05 \(\pm\) 22.19 & 75.35 \(\pm\) 23.75 & 0.93 \\ CRP (mg/dL) & 2.43 \(\pm\) 4.03 & 2.60 \(\pm\) 4.07 & 0.79 \\ GGT (mg/dL) & 48.81 \(\pm\) 37.54 & 50.62 \(\pm\) 56 & 0.79 \\ Total cholesterol (mg/dL) & 194.59 \(\pm\) 50.60 & 184.66 \(\pm\) 47.18 & 0.21 \\ Triglyceride (mg/dL) & 225 \(\pm\) 199.28 & 187.94 \(\pm\) 157.39 & 0.22 \\ LDL (mg/dL) & 126.09 \(\pm\) 53.75 & 115.62 \(\pm\) 43.35 & 0.20 \\ HDL (mg/dL) & 35.11 \(\pm\) 7.01 & 36.34 \(\pm\) 8.27 & 0.30 \\ Non-HDL cholesterol (mg/dL) & 159.48 \(\pm\) 48.96 & 148.32 \(\pm\) 45.56 & 0.15 \\ Cholesterol/HDL cholesterol & 5.67 \(\pm\) 1.65 & 5.25 \(\pm\) 1.52 & 0.11 \\ LDL cholesterol/HDL cholesterol & 3.70 \(\pm\) 1.77 & 3.23 \(\pm\) 1.35 & 0.08 \\ Triglycerides/HDL cholesterol & 6.88 \(\pm\) 7.05 & 5.83 \(\pm\) 5.99 & 0.33 \\ \hline \hline \end{tabular} Abbreviations: DES, drug eluting stent; SD, standard deviation; WBC, white blood cells; GFR, glomerular filtration rate; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; LDL, low-density lipoprotein; HDL, high-density lipoprotein.  
\end{table}
Table 4: Laboratory tests.  
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Angiographic Characteristics** & **2 nd Generation DES** & **Other Stents** & \\  & **(_n = 151_)** & **(_n = 53_)** & **\(p\)-Value** \\ \hline Treated vessel: LM, \(n\) (\%) & 2 (1.32) & 0 & 0.40 \\ Treated vessel: LAD, \(n\) (\%) & 68 (45.03) & 23 (43.39) & 0.84 \\ Treated vessel: LCX, \(n\) (\%) & 37 (24.50) & 7 (13.20) & 0.09 \\ Treated vessel: RCA, \(n\) (\%) & 43 (28.47) & 21 (39.62) & 0.13 \\ Treated vessel: CABG graft, \(n\) (\%) & 1 (0.66) & 0 & 0.55 \\ Single-vessel disease, \(n\) (\%) & 57 (37.74) & 27 (50.94) & 0.09 \\ Multivessel disease, \(n\) (\%) & 95 (62.91) & 25 (47.16) & 0.05 \\ Prior PCI in the index segments, \(n\) (\%) & 3 (1.98) & 2 (3.77) & 0.47 \\ Culprit lesion stenosis severity, (\%), mean \(\pm\) SD & 94.05 \(\pm\) 7.52 & 95.69 \(\pm\) 14.87 & 0.30 \\ Thrombus aspiration, \(n\) (\%) & 18 (11.92) & 9 (16.98) & 0.35 \\ Otstial lesion, \(n\) (\%) & 26 (17.21) & 5 (9.43) & 0.18 \\ TIMI 0–1 flow, \(n\) (\%) & 91 (60.26) & 37 (69.81) & 0.22 \\ TIMI 2 flow, \(n\) (\%) & 57 (37.74) & 16 (30.18) & 0.32 \\ TIMI 3 flow, \(n\) (\%) & 3 (1.98) & 0 & 0.30 \\ Calcified lesion, \(n\) (\%) & 22 (14.56) & 9 (16.98) & 0.67 \\ Lenght stent per lesion (mm), mean \(\pm\) SD & 3.01 \(\pm\) 0.45 & 3.10 \(\pm\) 0.51 & 0.23 \\ Lesion severity & & & \\ Type A, \(n\) (\%) & 75 (49.66) & 11 (20.75) & 0.00 \\ Type B, \(n\) (\%) & 68 (45.03) & 37 (69.81) & 0.00 \\ Type C, \(n\) (\%) & 8 (5.29) & 5 (9.43) & 0.29 \\ Stent diameter (mm), mean \(\pm\) SD & 22.76 \(\pm\) 6.93 & 22.32 \(\pm\) 7.18 & 0.69 \\ Number of stents per & 1 (1:2) & 1 (1:2) & - \\ procedure, median (25 th and 75 th interquartile) & 16.56 \(\pm\) 3.94 & 16.26 \(\pm\) 3.89 & 0.6328 \\ Maximal inflation pressure (atm), mean \(\pm\) SD & 82(54.30) & 23(43.39) & 0.63 \\ \hline \hline \end{tabular}
\end{table}
Table 5: Baseline angiographic characteristics of patients underwent PCI.  
converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB), and statin) at hospital discharge (Table 6). No significant differences were observed between groups regarding administration of aspirin (\(p\) = 0.96), clopidogrel (\(p\) = 0.51), dicagrelor (\(p\) = 0.44) or their combination, beta-blockers (\(p\) = 0.46), ACEI or ARB (\(p\) = 0.87 and \(p\) = 0.81, respectively) and statins (\(p\) = 0.44).